A novel cognitive-neurophysiological state biomarker in premanifest Huntington's disease validated on longitudinal data
In several neurodegenerative diseases, like Huntington's disease (HD), treatments are still lacking. To determine whether a treatment is effective, sensitive disease progression biomarkers are especially needed for the premanifest phase, since this allows the evaluation of neuroprotective treat...
Gespeichert in:
| Veröffentlicht in: | Scientific reports 2013-05, Vol.3 (1), p.1797-1797, Article 1797 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1797 |
|---|---|
| container_issue | 1 |
| container_start_page | 1797 |
| container_title | Scientific reports |
| container_volume | 3 |
| creator | Beste, Christian Stock, Ann-Kathrin Ness, Vanessa Hoffmann, Rainer Lukas, Carsten Saft, Carsten |
| description | In several neurodegenerative diseases, like Huntington's disease (HD), treatments are still lacking. To determine whether a treatment is effective, sensitive disease progression biomarkers are especially needed for the premanifest phase, since this allows the evaluation of neuroprotective treatments preventing, or delaying disease manifestation. On the basis of a longitudinal study we present a biomarker that was derived by integrating behavioural and neurophysiological data reflecting cognitive processes of action control. The measure identified is sensitive enough to track disease progression over a period of only 6 month. Changes tracked were predictive for a number of clinically relevant parameters and the sensitivity of the measure was higher than that of currently used parameters to track prodromal disease progression. The study provides a biomarker, which could change practice of progression diagnostics in a major basal ganglia disease and which may help to evaluate potential neuroprotective treatments in future clinical trials. |
| doi_str_mv | 10.1038/srep01797 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3647202</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1349705146</sourcerecordid><originalsourceid>FETCH-LOGICAL-c438t-faf7429204e3b7e81d24699366fe9fd897e6bb22753e21668bfcf7e1de5dbdf53</originalsourceid><addsrcrecordid>eNplkU1rFTEYhYNYbGm78A9IwIUfMDr5mGSyKZSitlBwo-uQmbyZps5NxiRzpf_eyK2Xq80mIe-Tk3M4CL0k7QfSsv5jTrC0RCr5DJ3QlncNZZQ-Pzgfo_Oc79u6Oqo4US_QMWWio5KSE_TrEoe4hRmPcQq--C00AdYUl7uH7OMcJz-aGediCuDBx41JPyBhH_CSYGOCd5ALvl5D8WEqMbzJ2PoMJgPemtnb-sziGPAcw-TLan2oavXWnKEjZ-YM54_7Kfr--dO3q-vm9uuXm6vL22bkrC-NM05yqmoWYIOEnljKhVJMCAfK2V5JEMNAqewYUCJEP7jRSSAWOjtY17FTdLHTXdZhA3aEUJKZ9ZJ8jfKgo_H630nwd3qKW80El7SlVeDto0CKP9eaVm98HmGeTYC4Zk0YV7LtCBcVff0feh_XVBNXqjrltFeKV-rdjhpTzLU8tzdDWv2nUb1vtLKvDt3vyb_9VeD9Dsh1FCZIB18-UfsN8FeuDg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1897428994</pqid></control><display><type>article</type><title>A novel cognitive-neurophysiological state biomarker in premanifest Huntington's disease validated on longitudinal data</title><source>MEDLINE</source><source>Nature Free</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><source>Springer Nature OA Free Journals</source><creator>Beste, Christian ; Stock, Ann-Kathrin ; Ness, Vanessa ; Hoffmann, Rainer ; Lukas, Carsten ; Saft, Carsten</creator><creatorcontrib>Beste, Christian ; Stock, Ann-Kathrin ; Ness, Vanessa ; Hoffmann, Rainer ; Lukas, Carsten ; Saft, Carsten</creatorcontrib><description>In several neurodegenerative diseases, like Huntington's disease (HD), treatments are still lacking. To determine whether a treatment is effective, sensitive disease progression biomarkers are especially needed for the premanifest phase, since this allows the evaluation of neuroprotective treatments preventing, or delaying disease manifestation. On the basis of a longitudinal study we present a biomarker that was derived by integrating behavioural and neurophysiological data reflecting cognitive processes of action control. The measure identified is sensitive enough to track disease progression over a period of only 6 month. Changes tracked were predictive for a number of clinically relevant parameters and the sensitivity of the measure was higher than that of currently used parameters to track prodromal disease progression. The study provides a biomarker, which could change practice of progression diagnostics in a major basal ganglia disease and which may help to evaluate potential neuroprotective treatments in future clinical trials.</description><identifier>ISSN: 2045-2322</identifier><identifier>EISSN: 2045-2322</identifier><identifier>DOI: 10.1038/srep01797</identifier><identifier>PMID: 23652721</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/378/2649/2150 ; 692/308/1892 ; 692/53/2423 ; 692/699/375/346 ; Adult ; Basal ganglia ; Biomarkers ; Biomarkers - metabolism ; Clinical trials ; Cognitive ability ; Disease Progression ; Female ; Humanities and Social Sciences ; Humans ; Huntington Disease - metabolism ; Huntington Disease - pathology ; Huntington's disease ; Huntingtons disease ; Longitudinal Studies ; Male ; Middle Aged ; multidisciplinary ; Neurodegenerative diseases ; Neuroprotection ; Neuropsychological Tests ; Science ; Young Adult</subject><ispartof>Scientific reports, 2013-05, Vol.3 (1), p.1797-1797, Article 1797</ispartof><rights>The Author(s) 2013</rights><rights>Copyright Nature Publishing Group May 2013</rights><rights>Copyright © 2013, Macmillan Publishers Limited. All rights reserved 2013 Macmillan Publishers Limited. All rights reserved</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c438t-faf7429204e3b7e81d24699366fe9fd897e6bb22753e21668bfcf7e1de5dbdf53</citedby><cites>FETCH-LOGICAL-c438t-faf7429204e3b7e81d24699366fe9fd897e6bb22753e21668bfcf7e1de5dbdf53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3647202/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3647202/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27901,27902,41096,42165,51551,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23652721$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Beste, Christian</creatorcontrib><creatorcontrib>Stock, Ann-Kathrin</creatorcontrib><creatorcontrib>Ness, Vanessa</creatorcontrib><creatorcontrib>Hoffmann, Rainer</creatorcontrib><creatorcontrib>Lukas, Carsten</creatorcontrib><creatorcontrib>Saft, Carsten</creatorcontrib><title>A novel cognitive-neurophysiological state biomarker in premanifest Huntington's disease validated on longitudinal data</title><title>Scientific reports</title><addtitle>Sci Rep</addtitle><addtitle>Sci Rep</addtitle><description>In several neurodegenerative diseases, like Huntington's disease (HD), treatments are still lacking. To determine whether a treatment is effective, sensitive disease progression biomarkers are especially needed for the premanifest phase, since this allows the evaluation of neuroprotective treatments preventing, or delaying disease manifestation. On the basis of a longitudinal study we present a biomarker that was derived by integrating behavioural and neurophysiological data reflecting cognitive processes of action control. The measure identified is sensitive enough to track disease progression over a period of only 6 month. Changes tracked were predictive for a number of clinically relevant parameters and the sensitivity of the measure was higher than that of currently used parameters to track prodromal disease progression. The study provides a biomarker, which could change practice of progression diagnostics in a major basal ganglia disease and which may help to evaluate potential neuroprotective treatments in future clinical trials.</description><subject>631/378/2649/2150</subject><subject>692/308/1892</subject><subject>692/53/2423</subject><subject>692/699/375/346</subject><subject>Adult</subject><subject>Basal ganglia</subject><subject>Biomarkers</subject><subject>Biomarkers - metabolism</subject><subject>Clinical trials</subject><subject>Cognitive ability</subject><subject>Disease Progression</subject><subject>Female</subject><subject>Humanities and Social Sciences</subject><subject>Humans</subject><subject>Huntington Disease - metabolism</subject><subject>Huntington Disease - pathology</subject><subject>Huntington's disease</subject><subject>Huntingtons disease</subject><subject>Longitudinal Studies</subject><subject>Male</subject><subject>Middle Aged</subject><subject>multidisciplinary</subject><subject>Neurodegenerative diseases</subject><subject>Neuroprotection</subject><subject>Neuropsychological Tests</subject><subject>Science</subject><subject>Young Adult</subject><issn>2045-2322</issn><issn>2045-2322</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNplkU1rFTEYhYNYbGm78A9IwIUfMDr5mGSyKZSitlBwo-uQmbyZps5NxiRzpf_eyK2Xq80mIe-Tk3M4CL0k7QfSsv5jTrC0RCr5DJ3QlncNZZQ-Pzgfo_Oc79u6Oqo4US_QMWWio5KSE_TrEoe4hRmPcQq--C00AdYUl7uH7OMcJz-aGediCuDBx41JPyBhH_CSYGOCd5ALvl5D8WEqMbzJ2PoMJgPemtnb-sziGPAcw-TLan2oavXWnKEjZ-YM54_7Kfr--dO3q-vm9uuXm6vL22bkrC-NM05yqmoWYIOEnljKhVJMCAfK2V5JEMNAqewYUCJEP7jRSSAWOjtY17FTdLHTXdZhA3aEUJKZ9ZJ8jfKgo_H630nwd3qKW80El7SlVeDto0CKP9eaVm98HmGeTYC4Zk0YV7LtCBcVff0feh_XVBNXqjrltFeKV-rdjhpTzLU8tzdDWv2nUb1vtLKvDt3vyb_9VeD9Dsh1FCZIB18-UfsN8FeuDg</recordid><startdate>20130508</startdate><enddate>20130508</enddate><creator>Beste, Christian</creator><creator>Stock, Ann-Kathrin</creator><creator>Ness, Vanessa</creator><creator>Hoffmann, Rainer</creator><creator>Lukas, Carsten</creator><creator>Saft, Carsten</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20130508</creationdate><title>A novel cognitive-neurophysiological state biomarker in premanifest Huntington's disease validated on longitudinal data</title><author>Beste, Christian ; Stock, Ann-Kathrin ; Ness, Vanessa ; Hoffmann, Rainer ; Lukas, Carsten ; Saft, Carsten</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c438t-faf7429204e3b7e81d24699366fe9fd897e6bb22753e21668bfcf7e1de5dbdf53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>631/378/2649/2150</topic><topic>692/308/1892</topic><topic>692/53/2423</topic><topic>692/699/375/346</topic><topic>Adult</topic><topic>Basal ganglia</topic><topic>Biomarkers</topic><topic>Biomarkers - metabolism</topic><topic>Clinical trials</topic><topic>Cognitive ability</topic><topic>Disease Progression</topic><topic>Female</topic><topic>Humanities and Social Sciences</topic><topic>Humans</topic><topic>Huntington Disease - metabolism</topic><topic>Huntington Disease - pathology</topic><topic>Huntington's disease</topic><topic>Huntingtons disease</topic><topic>Longitudinal Studies</topic><topic>Male</topic><topic>Middle Aged</topic><topic>multidisciplinary</topic><topic>Neurodegenerative diseases</topic><topic>Neuroprotection</topic><topic>Neuropsychological Tests</topic><topic>Science</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Beste, Christian</creatorcontrib><creatorcontrib>Stock, Ann-Kathrin</creatorcontrib><creatorcontrib>Ness, Vanessa</creatorcontrib><creatorcontrib>Hoffmann, Rainer</creatorcontrib><creatorcontrib>Lukas, Carsten</creatorcontrib><creatorcontrib>Saft, Carsten</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Scientific reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Beste, Christian</au><au>Stock, Ann-Kathrin</au><au>Ness, Vanessa</au><au>Hoffmann, Rainer</au><au>Lukas, Carsten</au><au>Saft, Carsten</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A novel cognitive-neurophysiological state biomarker in premanifest Huntington's disease validated on longitudinal data</atitle><jtitle>Scientific reports</jtitle><stitle>Sci Rep</stitle><addtitle>Sci Rep</addtitle><date>2013-05-08</date><risdate>2013</risdate><volume>3</volume><issue>1</issue><spage>1797</spage><epage>1797</epage><pages>1797-1797</pages><artnum>1797</artnum><issn>2045-2322</issn><eissn>2045-2322</eissn><abstract>In several neurodegenerative diseases, like Huntington's disease (HD), treatments are still lacking. To determine whether a treatment is effective, sensitive disease progression biomarkers are especially needed for the premanifest phase, since this allows the evaluation of neuroprotective treatments preventing, or delaying disease manifestation. On the basis of a longitudinal study we present a biomarker that was derived by integrating behavioural and neurophysiological data reflecting cognitive processes of action control. The measure identified is sensitive enough to track disease progression over a period of only 6 month. Changes tracked were predictive for a number of clinically relevant parameters and the sensitivity of the measure was higher than that of currently used parameters to track prodromal disease progression. The study provides a biomarker, which could change practice of progression diagnostics in a major basal ganglia disease and which may help to evaluate potential neuroprotective treatments in future clinical trials.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>23652721</pmid><doi>10.1038/srep01797</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2045-2322 |
| ispartof | Scientific reports, 2013-05, Vol.3 (1), p.1797-1797, Article 1797 |
| issn | 2045-2322 2045-2322 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3647202 |
| source | MEDLINE; Nature Free; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Free Full-Text Journals in Chemistry; Springer Nature OA Free Journals |
| subjects | 631/378/2649/2150 692/308/1892 692/53/2423 692/699/375/346 Adult Basal ganglia Biomarkers Biomarkers - metabolism Clinical trials Cognitive ability Disease Progression Female Humanities and Social Sciences Humans Huntington Disease - metabolism Huntington Disease - pathology Huntington's disease Huntingtons disease Longitudinal Studies Male Middle Aged multidisciplinary Neurodegenerative diseases Neuroprotection Neuropsychological Tests Science Young Adult |
| title | A novel cognitive-neurophysiological state biomarker in premanifest Huntington's disease validated on longitudinal data |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T20%3A32%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20novel%20cognitive-neurophysiological%20state%20biomarker%20in%20premanifest%20Huntington's%20disease%20validated%20on%20longitudinal%20data&rft.jtitle=Scientific%20reports&rft.au=Beste,%20Christian&rft.date=2013-05-08&rft.volume=3&rft.issue=1&rft.spage=1797&rft.epage=1797&rft.pages=1797-1797&rft.artnum=1797&rft.issn=2045-2322&rft.eissn=2045-2322&rft_id=info:doi/10.1038/srep01797&rft_dat=%3Cproquest_pubme%3E1349705146%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1897428994&rft_id=info:pmid/23652721&rfr_iscdi=true |